Trials in High Point, North Carolina
Here are the top 10 medical studies for lung cancer in High Point, North Carolina
Popular Filters
Phase 3 Trials
Tyrosine Kinase Inhibitor
Osimertinib + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Blacksburg, Virginia
This trial is testing whether adding chemotherapy to osimertinib will help people with non-small cell lung cancer that has a specific DNA mutation and has gotten worse despite osimertinib.
Chemotherapy
Pembrolizumab + Olaparib for Squamous Cell Carcinoma of the Lung
Recruiting1 awardPhase 3
Cary, North Carolina
This trial will compare two treatments for people with squamous non-small cell lung cancer. One treatment will be pembrolizumab plus maintenance olaparib, and the other will be pembrolizumab plus maintenance olaparib placebo. The study's two primary hypotheses are that pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival and overall survival.
PD-1 Inhibitor
Pembrolizumab + Olaparib/Pemetrexed for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Cary, North Carolina
This trial is comparing two treatment combinations for a specific type of lung cancer. It aims to find out which combination helps patients live longer and keeps their cancer from getting worse. The treatments work by boosting the immune system, making it harder for cancer cells to repair themselves, or stopping their growth.
Trials With No Placebo
CAR T-cell Therapy
ADP-A2M4CD8 + Immunotherapy for Advanced Cancers
Recruiting1 awardPhase 1
Durham, North Carolina
This trial tests a new therapy that uses modified immune cells to fight various cancers in patients with specific markers. The treatment aims to boost the immune system by using trained cells to target and destroy cancer cells.
Tyrosine Kinase Inhibitor
Osimertinib + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Blacksburg, Virginia
This trial is testing whether adding chemotherapy to osimertinib will help people with non-small cell lung cancer that has a specific DNA mutation and has gotten worse despite osimertinib.
PD-1 Inhibitor
Pembrolizumab + Olaparib/Pemetrexed for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Cary, North Carolina
This trial is comparing two treatment combinations for a specific type of lung cancer. It aims to find out which combination helps patients live longer and keeps their cancer from getting worse. The treatments work by boosting the immune system, making it harder for cancer cells to repair themselves, or stopping their growth.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.